Orencia® ClickjectTM (abatacept) 125mg/1ml solution for injection pre-filled pens will be out of stock from mid-June 2024 due to a manufacturing issue resulting in delays in production. From late August, Bristol-Myers Squibb will start to build their stockholding to ensure continuity of supply moving forward. Affected patients should only be switched back to pre-filled pens once supply resilience is confirmed. Homecare providers (Lloyds Pharmacy Clinical Homecare (LPCH), HealthNet and Polar Speed) have sufficient stock to supply existing patients until week ending 23 June 2024. Orencia® 125mg/1ml solution for injection pre-filled syringes (PFS) remain available, however, can only support 15% of patients switching to them (see Additional information). 

Orencia® 50mg and 87.5mg solution for injection PFS are not currently marketed. 

Orencia® 250mg powder for concentrate for solution for infusion vials remain available and can support a full increase in demand.